Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients
Barbara Kornek, Fritz Leutmezer, Paulus Rommer, et al.
Annals of Neurology (2022) Vol. 91, Iss. 3, pp. 342-352
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
Nik Krajnc, Gabriel Bsteh, Thomas Berger, et al.
Neurotherapeutics (2022) Vol. 19, Iss. 3, pp. 753-773
Open Access | Times Cited: 44
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42
Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms
Brent Brown, Vanshika Ojha, Ingo Fricke, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 408-408
Open Access | Times Cited: 37
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
Susana Otero‐Romero, Christine Lebrun‐Frénay, Saúl Reyes, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 8, pp. 904-925
Open Access | Times Cited: 29
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial
Cory A. Perugino, Zachary S. Wallace, Debra Zack, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 8, pp. e442-e450
Closed Access | Times Cited: 24
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Frontiers in CAR-T cell therapy for autoimmune diseases
Yan-Ruide Li, Zibai Lyu, Yuning Chen, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 9, pp. 839-857
Open Access | Times Cited: 7
A Machine Learning approach to identify groups of patients with hematological malignant disorders
Pablo Rodríguez-Belenguer, José Luís Piñana, Manuel Sánchez-Montañés, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 246, pp. 108011-108011
Open Access | Times Cited: 5
Long-term antibody responses to COVAXIN and COVISHIELD vaccines in rheumatoid arthritis patients and healthy control population – A cross-sectional study
Vijaya Prasanna Parimi, Anand Pyati, Madhavi Eerike
Journal of Family Medicine and Primary Care (2025) Vol. 14, Iss. 1, pp. 107-114
Open Access
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
Susana Otero‐Romero, Christine Lebrun‐Frénay, Saúl Reyes, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 8, pp. 2144-2176
Open Access | Times Cited: 12
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year
Giulio Disanto, Alice Galante, Marco Cantu', et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations
Maura Pugliatti, Thomas Berger, Hans‐Peter Hartung, et al.
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 319-327
Closed Access | Times Cited: 18
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
Alvina Widhani, Anshari Saifuddin Hasibuan, Retia Rismawati, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1456-1456
Open Access | Times Cited: 10
Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
Gabriel Bsteh, Harald Hegen, Gerhard Traxler, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 5, pp. 1538-1544
Open Access | Times Cited: 16
Klinische Verläufe und Kosten für Hospitalisierungen von COVID-19-Patienten mit potenziell eingeschränktem Immunsystem in Deutschland
Dennis Häckl, Marc Pignot, Phi Long Dang, et al.
DMW - Deutsche Medizinische Wochenschrift (2024) Vol. 149, Iss. 07, pp. e38-e46
Open Access | Times Cited: 2
Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants
Hao Zhou, Ping Leng, Yang Wang, et al.
Science Bulletin (2024) Vol. 69, Iss. 15, pp. 2456-2470
Closed Access | Times Cited: 2
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
Georges Katoul Al Rahbani, Christina Woopen, Marie Dunsche, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 684-684
Open Access | Times Cited: 2
Impact of vaccination on COVID ‐19 outcome in multiple sclerosis
Gabriel Bsteh, Christiane Gradl, Bettina Heschl, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 11, pp. 3329-3336
Open Access | Times Cited: 12
Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy
Davide Firinu, Giuseppe Fenu, Giuseppina Sanna, et al.
Journal of Autoimmunity (2022) Vol. 131, pp. 102848-102848
Open Access | Times Cited: 10
From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases
E. Lee, Ji Eun Oh
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
José Luís Piñana, Lourdes Vázquez, Inmaculada Heras, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2
Κonstantinos Thomas, Ioannis Grigoropoulos, Panagiota Alexopoulou, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 534-541
Open Access | Times Cited: 4
Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis
Theodoros Marantos, Evdoxia Kyriazopoulou, Vasileios Lekakis, et al.
Journal of the Neurological Sciences (2023) Vol. 456, pp. 122852-122852
Closed Access | Times Cited: 4
Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
Nik Krajnc, Harald Hegen, Gerhard Traxler, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 65, pp. 104009-104009
Open Access | Times Cited: 7
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Maura Pugliatti, Hans‐Peter Hartung, Celia Oreja‐Guevara, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top